GEAN TO 2 — Genetic Analysis As Balance Sheet
0.000.00%
Last trade - 00:00- NOK23.17m
- NOK19.32m
- NOK11.16m
Annual balance sheet for Genetic Analysis As, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | — | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 20.3 | 4.01 | 24.2 | 46.8 | 25.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6.02 | 12.2 | 1.93 | 8.42 | 8.36 |
| Total Inventory | |||||
| Total Current Assets | 26.3 | 16.9 | 28 | 57.6 | 35.4 |
| Net Property, Plant And Equipment | 1.37 | 3.13 | 1.62 | 1.59 | 8.14 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 46.4 | 45.6 | 55.6 | 83.5 | 64.4 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.77 | 9.26 | 7.59 | 9.97 | 12.9 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7.92 | 12.1 | 9 | 11.4 | 20.3 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 38.5 | 33.5 | 46.6 | 72.1 | 44.1 |
| Total Liabilities & Shareholders' Equity | 46.4 | 45.6 | 55.6 | 83.5 | 64.4 |
| Total Common Shares Outstanding |